Page last updated: 2024-12-05

oxotremorine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxotremorine is a synthetic cholinergic agonist that acts primarily on the muscarinic acetylcholine receptors. It is known for its potent tremor-inducing properties in animals and humans, hence its name. It was initially synthesized in the 1950s as a potential therapeutic agent for Parkinson's disease but was found to have limited clinical value. However, it has become a valuable tool for research into the cholinergic system, particularly in understanding the role of muscarinic receptors in various physiological processes, including learning, memory, and movement. The compound's effects are attributed to its ability to mimic the actions of acetylcholine at muscarinic receptors, leading to a range of physiological responses, including increased salivation, bronchoconstriction, and gastrointestinal motility. Its tremor-inducing effects, along with its ability to affect other physiological functions, make it a valuable research tool for studying the cholinergic system and developing new therapeutic approaches for a range of disorders.'

Oxotremorine: A non-hydrolyzed muscarinic agonist used as a research tool. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4630
CHEMBL ID7634
CHEBI ID7851
SCHEMBL ID2128
MeSH IDM0015658

Synonyms (88)

Synonym
1-(4-(1-pyrrolidinyl)-2-butynyl)-2-pyrrolidinone
1-(4-(pyrrolidin-1-yl)but-2-ynyl)pyrrolidin-2-one
einecs 200-728-0
nsc 330497
brn 1530948
2-pyrrolidinone, 1-(4-(1-pyrrolidinyl)-2-butynyl)-
AB00053670-07
BRD-K21936341-051-02-4
gtpl302
DIVK1C_000410
KBIO1_000410
2'-oxopyrrolidino-1-pyrrolidino-4-butyne
oxotremorin
nsc-330497
oxytremorine
mls000766260 ,
wln: t5nvtj a2uu2- at5ntj
nsc330497
tremorine, oxo-
2-pyrrolidinone, 1-[4-(1-pyrrolidinyl)-2-butynyl]-
1-[4-(1-pyrrolidinyl)-2-butynyl]-2-pyrrolidinone
SPECTRUM_001875
SPECTRUM_001448
SPECTRUM5_001686
tocris-0843
NCGC00024821-01
NCGC00015773-01
lopac-o-9126
LOPAC0_000914
BSPBIO_003198
SPECTRUM5_001099
oxotremorine
70-22-4
C07485
IDI1_000410
NCGC00024821-03
smr000528860
KBIO2_007064
KBIOGR_001404
KBIOSS_001928
KBIOSS_002398
KBIO2_004496
KBIO2_007529
KBIO2_002393
KBIO2_001928
KBIO2_004961
KBIO3_002698
SPECTRUM4_000912
SPECTRUM2_001568
SPECTRUM3_001599
NINDS_000410
SPBIO_001476
NCGC00024821-02
HMS2089F17
NCGC00015773-05
L001302
CHEMBL7634 ,
chebi:7851 ,
cid_4630
(oxotremorine)1-(4-pyrrolidin-1-yl-but-2-ynyl)-pyrrolidin-2-one
1-[4-(2-oxo-pyrrolidin-1-yl)-but-2-ynyl]-pyrrolidinium
bdbm50004665
1-(4-pyrrolidin-1-yl-but-2-ynyl)-pyrrolidin-2-one (oxotremorphine)
oxotremorine1-(4-pyrrolidin-1-yl-but-2-ynyl)-pyrrolidin-2-one
1-(4-pyrrolidin-1-yl-but-2-ynyl)-pyrrolidin-2-one
1-(4-pyrrolidin-1-yl-but-2-ynyl)-pyrrolidin-2-one(oxotremorine)
1-(4-pyrrolidin-1-ylbut-2-ynyl)pyrrolidin-2-one
CCG-204996
HMS2231C13
NCGC00015773-04
NCGC00015773-02
NCGC00015773-03
5ry0uwh1jl ,
unii-5ry0uwh1jl
FT-0631303
2-pyrrolidinone,1-[4-(1-pyrrolidinyl)-2-butyn-1-yl]-
HMS3372G17
oxotremorine [mi]
1-(2-oxopyrrolidino)-4-pyrrolidino-2-butyne
SCHEMBL2128
1-(4-pyrrolidino-2-butynyl)-2-pyrrolidinone
DTXSID10220252
1-(4-(pyrrolidin-1-yl)but-2-yn-1-yl)pyrrolidin-2-one
SR-01000075154-3
Q676896
SDCCGSBI-0050889.P003
NCGC00015773-10
oxotremorine-sesquifumarate

Research Excerpts

Overview

Oxotremorine (OXO) is a cholinergic agonist that increases cerebral blood flow (CBF) when administered intravenously. It is a muscarinic receptor agonist and induces a variety of physiological and behavioural effects.

ExcerptReferenceRelevance
"Oxotremorine, which is a close analogue of oxotremorine-M, and xanomeline, a chemically distinct muscarinic agonist, did not potentiate NMDA receptors by this direct mechanism."( Oxotremorine-M potentiates NMDA receptors by muscarinic receptor dependent and independent mechanisms.
Reed, H; Sher, E; Zwart, R, 2018
)
2.64
"Oxotremorine is a cholinergic agonist known to induce acute hypothermia."( Oxotremorine-induced hypothermia as a method for evaluating long-term neuronal changes following poisoning by cholinesterase inhibitors in rats.
Grauer, E; Levy, A, 2007
)
2.5
"Oxotremorine (OXO) is a cholinergic agonist that increases cerebral blood flow (CBF) when administered intravenously. "( Time-dependent inhibition of oxotremorine-induced cerebral hyperemia by N omega-nitro-L-arginine in cats.
Clavier, N; Kirsch, JR; Tietjen, CS; Traystman, RJ, 1995
)
2.03
"Oxotremorine is a muscarinic receptor agonist that induces a variety of physiological and behavioural effects including hypothermia in mice. "( The characterization of oxotremorine-induced hypothermic response in the rat.
Chambers, PL; Kelly, JP; Leonard, BE; Ryan, PM, 1996
)
2.04

Effects

Oxotremorine tremor has in common with shivering its frequency range (10-28 Hz) and the co-contraction of flexors and extensors.

ExcerptReferenceRelevance
"[3H]Oxotremorine-M has been used as a ligand to label muscarinic binding sites on membranes prepared from rat fore-brain and heart. "( [3H]oxotremorine-M binding to membranes prepared from rat brain and heart: evidence for subtypes of muscarinic receptors.
Bevan, P, 1984
)
1.38
"Oxotremorine tremor has in common with shivering its frequency range (10-28 Hz) and the co-contraction of flexors and extensors."( Role of the stretch reflex in oxotremorine tremor.
Decima, EE, 1996
)
1.3
"Two oxotremorine antagonists have been examined using oxotremorine as the tremor salivation inducer and the ratios between the central and peripheral nervous systems determined. "( The central and peripheral effectiveness of two oxotremorine-antagonists determined using oxotremorine-induced tremor and salivation.
Eicholzer, A; Ogren, SO, 1977
)
1.07

Actions

Oxotremorine tended to increase amphetamine-stimulated preproenkephalin messenger RNA expression, but the effect did not reach statistical significance. Oxot Remorine had lower activity and (+)-(R)-BM-5 was essentially inactive at comparable concentrations.

ExcerptReferenceRelevance
"Oxotremorine tended to increase amphetamine-stimulated preproenkephalin messenger RNA expression, but the effect did not reach statistical significance."( Muscarinic receptors regulate striatal neuropeptide gene expression in normal and amphetamine-treated rats.
McGinty, JF; Wang, JQ, 1996
)
1.02
"Oxotremorine had lower activity and (+)-(R)-BM-5 was essentially inactive at comparable concentrations."( Stereoselective binding and activity of oxotremorine analogs at muscarinic receptors in rat brain.
Abuh, YF; Dokas, LA; Dunbar, PG; Hacksell, U; Hoss, W; Messer, WS; Ngur, DO; Nilsson, BM; Ting, SM, 1992
)
1.27
"Oxotremorine's potency to produce response rate suppression decreased in rats receiving physostigmine three times daily but did not substantially change in rats receiving single daily injections."( Tolerance to oxotremorine's effects on schedule-controlled behavior in physostigmine-tolerant rats.
Elsmore, TF; Genovese, RF; King, LR, 1988
)
1.37

Treatment

Oxotremorine treatment (0.1 or 0.2 mg/kg, i.p.) to stressed rats resulted in a significant increase in the percent correct choices and a decrease in the number of RMEs compared with stress as well as the stress+vehicle-treated groups. Oxot Remorine-M pretreatment protected cells from H(2)O(2)-induced caspase-3 activation and death.

ExcerptReferenceRelevance
"Oxotremorine-M treatment produced a significant increase in the primary neurite outgrowth that was blocked by pre-treatment with the pFGFR inhibitor SU5402 and Src inhibitors."( Existence of muscarinic acetylcholine receptor (mAChR) and fibroblast growth factor receptor (FGFR) heteroreceptor complexes and their enhancement of neurite outgrowth in neural hippocampal cultures.
Belluardo, N; Borroto-Escuela, DO; Di Liberto, V; Frinchi, M; Fuxe, K; Mudò, G; Verdi, V, 2017
)
1.18
"Oxotremorine-M pretreatment protected cells from H(2)O(2)-induced caspase-3 activation and death, and this was equivalent to protection afforded by a caspase inhibitor."( Muscarinic receptor activation protects cells from apoptotic effects of DNA damage, oxidative stress, and mitochondrial inhibition.
De Sarno, P; Jope, RS; King, TD; Shestopal, SA; Song, L; Zmijewska, A, 2003
)
1.04
"Oxotremorine treatment (0.1 or 0.2 mg/kg, i.p.) to stressed rats resulted in a significant increase in the percent correct choices and a decrease in the number of RMEs compared with stress as well as the stress+vehicle-treated groups."( The involvement of cholinergic and noradrenergic systems in behavioral recovery following oxotremorine treatment to chronically stressed rats.
Raju, TR; Shankaranarayana Rao, BS; Srikumar, BN, 2006
)
1.28
"Oxotremorine treatment significantly reduced QNB binding in every brain region."( Genetic influences on tolerance development with chronic oxotremorine infusion.
Collins, AC; Marks, MJ; Romm, E, 1987
)
1.24
"Treatment with Oxotremorine-M significantly increased the level of phosphorylated HSF1 in all time points studied, without change of protein levels."( Heat shock protein (Hsp) regulation by muscarinic acetylcholine receptor (mAChR) activation in the rat hippocampus.
Belluardo, N; Cappello, F; Frinchi, M; Mudò, G; Scaduto, P, 2018
)
0.82
"Pretreatment with oxotremorine-M, a selective agonist of muscarinic receptors that are expressed endogenously in these cells, did not affect the accumulation of p53 but greatly attenuated caspase-3 activation and protected from cell death to nearly the same extent as treatment with a general caspase inhibitor."( Muscarinic receptor activation protects cells from apoptotic effects of DNA damage, oxidative stress, and mitochondrial inhibition.
De Sarno, P; Jope, RS; King, TD; Shestopal, SA; Song, L; Zmijewska, A, 2003
)
0.64
"In untreated rats, oxotremorine methiodide elicited a bimodal response consisting of an initial increase in bladder capacity, maximal voiding pressure, pressure threshold and post voiding intravesical pressure, but reduced voiding efficiency and bladder compliance."( Role of protein kinase C in central muscarinic inhibitory mechanisms regulating voiding in rats.
De Groat, WC; Ishiura, Y; Nakamura, Y; Namiki, M; Yokoyama, O, 2003
)
0.64
"Pretreatment with oxotremorine-M (Oxo-M) caused the increase in phytohemagglutinin-induced IL-2 production."( The presence and functions of muscarinic receptors in human T cells: the involvement in IL-2 and IL-2 receptor system.
Hosoi, T; Nomura, J; Nomura, Y; Okuma, Y, 2003
)
0.64
"Pretreatment with oxotremorine (0.25 mg/kg, s.c.) significantly attenuated amphetamine (1.25 and 2.5 mg/kg, i.p.)-stimulated striatal preprodynorphin and, to a lesser degree, substance P messenger RNA expression."( Muscarinic receptors regulate striatal neuropeptide gene expression in normal and amphetamine-treated rats.
McGinty, JF; Wang, JQ, 1996
)
0.62
"Treatment with oxotremorine or nicotine (multiple injections for 2 or 3 days) induced analogous changes for peptide and mRNA levels, however, the increases were smaller and for the mRNA less consistent."( Stimulation of rat adrenal medulla can induce differential changes in the peptide and mRNA levels of chromogranins, neuropeptides and other constituents of chromaffin granules.
Fischer-Colbrie, R; Fleming, PJ; Höfle, G; Hogue-Angeletti, R; Humpel, C; Laslop, A; Saria, A; Weiler, R; Winkler, H; Wohlfarter, T, 1991
)
0.62
"Pretreatment with oxotremorine also reduced the density of muscarinic receptors without affecting the affinity of these sites for [3H]quinuclidinyl benzilate."( Muscarinic cholinergic receptors in mouse pituitary tumor cells: prolonged agonist pretreatment decreases receptor content and increases forskolin- and hormone-stimulated cyclic AMP synthesis and adrenocorticotropin secretion.
Desjardins, D; Heisler, S; Nguyen, MH, 1985
)
0.59
"Treatment with oxotremorine caused down-regulation of muscarinic receptors, while treatment with nicotine caused up-regulation of nicotinic receptors."( Tolerance, cross-tolerance, and receptors after chronic nicotine or oxotremorine.
Collins, AC; Marks, MJ, 1985
)
0.84

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic parameters of muscarinic cholinergic drugs after intravenous (IV) and oral administration to mice was determined with ex vivo (3H)-oxotremorine-M (3H-Oxt) binding to the brain."( Pharmacokinetics of muscarinic cholinergic drugs as determined by ex vivo (3H)-oxotremorine-M binding.
Francis, JW; Sethy, VH, 1990
)
0.71
"The pharmacodynamic activity of (+/-)-1-[4-(2-isopropoxyethoxymethyl)-phenoxy]-3-isopropylamino-2- propranol- hemifumarate (bisoprolol, EMD 33 512) has been investigated under in vitro and in vivo conditions."( Pharmacodynamic profile of the selective beta 1-adrenoceptor antagonist bisoprolol.
Becker, KH; Bergmann, R; Bourgois, R; Enenkel, HJ; Fuchs, A; Harting, J; Jonas, R; Lettenbaur, H; Minck, KO; Schelling, P, 1986
)
0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
" The effect of a drug combination on retention was found to be dependent on the particular drugs in the combination, the ratio and the dose administered."( Two-drug combinations of memory enhancers: effect of dose ratio upon potency and therapeutic window, in mice.
Cherkin, A; Flood, JF; Smith, GE, 1988
)
0.27

Bioavailability

ExcerptReferenceRelevance
" It was poorly absorbed both by the oral and the aerosol routes and it did not appear to penetrate the blood-brain barrier."( LG 30435 is a new bronchodilator agent with multiple sites of action.
Criscuoli, M; Renzetti, AR; Subissi, A, 1986
)
0.27

Dosage Studied

The non-selective phosphodiesterase inhibitor isobutylmethylxanthine (IBMX) (1 mM) resulted in a more severe suppression of the histamine and pilocarpine responses. Pirenzepine, and M1 selective antagonist, produced a parallel shift in the oxotremorine dose-response curve, indicating that the enhanced hypnotic sensitivity to ethanol may be due to interaction with M1 muscarinic receptors.

ExcerptRelevanceReference
"2 In both species the slope of the dose-response curve was greater for oxotremorine (8."( Is acetylcholine involved in a dopamine receptor mediated hypothermia in mice and rats?
Cox, B; Lee, TF, 1978
)
0.49
" Neither the control rate of ACh release nor the dose-response curve for atropine were altered by (a) an 8-day morphine injection schedule, and (b) exposure of the tissue to morphine in the bath for 90 min."( Muscarinic feedback inhibition of acetylcholine release from the myenteric plexus in the quinea pig ileum and its status after chronic exposure to morphine.
Jhamandas, K; Sawynok, J, 1977
)
0.26
" The muscarinic antagonists pirenzepine, (+-)-5,11-dihydro-11-[[[2-[2-((dipropylamino)methyl)-1-piperidinyl] ethyl]amino]-carbonyl]-6H-pyrido(2,3-b)(1,4)-benzodiazepin-6-one (AF-DX 384), 11-[[4-[4-(diethylamino)butyl]-1-piperidinyl]acetyl]-5,11-dihydro- 6H-pyrido(2,3-b)(1,4)-benzodiazepin-6-one (AQ-RA 741), p-fluorohexahydro-sila-difenidol (p-F-HHSiD), 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP) and (R)- and (S)-hexahydro-difenidol [(R)-HHD, (S)-HHD] shifted the muscarine, methacholine or carbachol dose-response curve to the right in a competitive manner."( Characterization of muscarinic receptors mediating vasodilation in guinea-pig ileum submucosal arterioles by the use of computer-assisted videomicroscopy.
Bungardt, E; Feifel, R; Lambrecht, G; Moser, U; Mutschler, E; Surprenant, A; Tacke, R; Vockert, E, 1992
)
0.28
" Addition of the muscarinic antagonists atropine or pirenzepine shifted the carbachol dose-response curves to the right, without decreasing the carbachol maximal stimulatory effects."( Effects of muscarinic agonists and depolarizing agents on inositol monophosphate accumulation in the rabbit vagus nerve.
Dunant, Y; Sierro, CD; Vitus, J, 1992
)
0.28
"3 microM) shifted the dose-response curve to the right in a parallel manner."( Muscarinic receptor is coupled with a cation channel through a GTP-binding protein in guinea-pig chromaffin cells.
Inoue, M; Kuriyama, H, 1991
)
0.28
" The non-selective phosphodiesterase inhibitor isobutylmethylxanthine (IBMX) (1 mM) resulted in a more severe suppression of the histamine and pilocarpine responses and also produced a significant suppression of the maximal response to oxotremorine and a small shift in the carbachol dose-response curve."( Beta-adrenoceptor induced inhibition of muscarinic receptor-stimulated phosphoinositide metabolism is agonist specific in bovine tracheal smooth muscle.
Chilvers, ER; Nahorski, SR; Offer, GJ, 1991
)
0.46
" Oxotremorine-induced tremor and salivation in mice were delayed after extremely high dosage of levocabastine; however, these were much less effective than those seen after diphenhydramine and ketotifen."( Central effect of the potent long-acting H1-antihistamine levocabastine.
Aoki, I; Kamei, C; Tasaka, K; Tsujimoto, S; Yoshida, T, 1990
)
1.19
" Analysis of the dose-response curves for contraction and inositol phosphates accumulation with these agonists demonstrated a direct relationship between the two parameters, with a considerable reserve of inositol phosphate production for the full contractile agonists, methacholine and oxotremorine, and no reserve for the partial agonist, McN-A-343."( Evidence for a direct relationship between phosphoinositide metabolism and airway smooth muscle contraction induced by muscarinic agonists.
Elzinga, CR; Kauffman, HF; Meurs, H; Postema, JB; Roffel, AF; Timmermans, A; Zaagsma, J, 1988
)
0.45
" Moreover, PDBu, which causes attenuation of the maximal response to vasoactive intestinal polypeptide (VIP), also induced a small right shift in the dose-response curve for VIP-induced cyclic AMP accumulation."( Regulation of GH3 pituitary tumour-cell adenylate cyclase activity by activators of protein kinase C.
Brown, BL; Dobson, PR; Quilliam, LA, 1989
)
0.28
" In spite of the fact that there was a doubling of the density of M2 sites, no significant differences in dose-response curves for carbachol-induced inhibition of [3H]cAMP accumulation were observed in slices of CTX plus DH from control and l-atropine-treated rats."( Regulation of muscarinic receptor subtypes and their responsiveness in rat brain following chronic atropine administration.
Lee, W; Wolfe, BB, 1989
)
0.28
" S1 served as a control and at S2-4 oxotremorine dose-response curves were taken expressing the dose-related inhibition of the evoked release of [3H]norepinephrine as percentage of the control."( Antagonism by tricyclic antidepressants of the muscarinic receptors located on the adrenergic nerve endings in rabbit heart atrium.
Perel, JM; Somogyi, GT, 1989
)
0.55
" Tolerance to oxotremorine was evaluated after treatment by constructing cumulative dose-response curves and measuring body temperature and rotarod performance."( The effects of chronic oxotremorine treatment on spatial learning and tolerance development in mice.
Upchurch, M; Wehner, JM, 1989
)
0.95
" Dose-response curves to carbachol, muscarine and oxotremorine were shifted to the right by gallamine and pirenzepine in a parallel manner with no change in maximal response ostensibly indicating simple competitive inhibition."( Pharmacologic discrimination between receptor heterogeneity and allosteric interaction: resultant analysis of gallamine and pirenzepine antagonism of muscarinic responses in rat trachea.
Boselli, C; Kenakin, T, 1989
)
0.53
" We established dose-response curves by fluorometric measurement of Ca2+ mobilization in cell suspensions of whole chick embryos stage 23/24."( The muscarinic receptor of chick embryo cells: correlation between ligand binding and calcium mobilization.
Drews, U; Oettling, G; Schmidt, H, 1985
)
0.27
" This effect proved to be receptor-mediated because preincubation with 10(-5)M atropine shifted the dose-response curve one order of magnitude rightward."( Intact human lymphocyte membranes respond to muscarinic receptor stimulation by oxotremorine with marked changes in microviscosity and an increase in cyclic GMP.
Consolo, S; Ladinsky, H; Masturzo, P; Nordstrom, O; Salmona, M, 1985
)
0.5
" Gallamine caused parallel shifts to the right in the dose-response curves for inhibition of adenylate cyclase activity by the highly efficacious muscarinic agonist oxotremorine-M and the partial agonist Bm 5 [N-methyl-N-(1-methyl-4-pyrrolidino)-2-butynyl acetamide]."( Gallamine allosterically antagonizes muscarinic receptor-mediated inhibition of adenylate cyclase activity in the rat myocardium.
Ehlert, FJ, 1988
)
0.47
" Pirenzepine, and M1 selective antagonist, produced a parallel shift in the oxotremorine dose-response curve, indicating that the enhanced hypnotic sensitivity to ethanol may be due to interaction of oxotremorine with M1 muscarinic receptors."( Central muscarinic cholinergic influences on ethanol sensitivity in long-sleep and short-sleep mice.
Erwin, VG; Jones, BC; Korte, A, 1988
)
0.5
" The dose-response curves showed that AF102B was far less potent than oxotremorine at the hippocampal presynaptic muscarinic receptors (autoreceptors)."( Heterogeneity of muscarinic autoreceptors and heteroreceptors in the rat brain: effects of a novel M1 agonist, AF102B.
Kawanishi, G; Mizobe, F; Ohgane, N; Ono, S; Saito, Y, 1988
)
0.51
" Some combinations of cholinergic drugs enhance retention even though the total drug dosage is reduced by as much as 97% compared to the dose needed to improve retention when the same drugs are administered singly."( Two-drug combinations of memory enhancers: effect of dose ratio upon potency and therapeutic window, in mice.
Cherkin, A; Flood, JF; Smith, GE, 1988
)
0.27
" For drug-treated BALB mice, the dose-response curves for both measures were parallel to those for saline-treated mice, while for DBA and C3H mice the slopes of the dose-response curves were significantly less for treated mice than they were for controls."( Genetic influences on tolerance development with chronic oxotremorine infusion.
Collins, AC; Marks, MJ; Romm, E, 1987
)
0.52
" Dose-response curves for GDP, GTP, and guanyl-5'-yl imidodiphosphate showed them to be equipotent."( Guanine nucleotide regulation of a mammalian myocardial muscarinic receptor system. Evidence for homo- and heterotropic cooperativity in ligand binding analyzed by computer-assisted curve fitting.
Birnbaumer, L; Entman, ML; Mattera, R; Pitts, BJ, 1985
)
0.27
" In hexamethonium, pirenzepine shifted the acetylcholine dose-response curve to the right with an equilibrium dissociation constant of 200 nM, indicating an interaction with a m2-type of muscarinic receptor."( Acetylcholine acts on m2-muscarinic receptors to excite rat locus coeruleus neurones.
Egan, TM; North, RA, 1985
)
0.27
" A dose-response curve was determined for each of four drugs (arecoline, edrophonium, oxotremorine, tacrine) and for each of the six possible two-drug combinations."( Memory enhancement: supra-additive effect of subcutaneous cholinergic drug combinations in mice.
Cherkin, A; Flood, JF; Smith, GE, 1985
)
0.49
" Dose-response curves for pilocarpine and oxotremorine effects are not appreciably affected either by pretreatment with methylatropine (1."( Microwave facilitation of methylatropine antagonism of central cholinomimetic drug effects.
Fujimoto, JM; Ishii, TK; Lange, DG; Quock, RM, 1986
)
0.54
" The method used involved analysis of dose-response data before and after fractional inactivation of receptors with propylbenzilylcholine mustard."( Structural requirements for muscarinic receptor occupation and receptor activation by oxotremorine analogs in the guinea-pig ileum.
Ringdahl, B, 1985
)
0.49
" Dose-response curves obtained in the presence of oxotremorine-M for inositol lipid turnover in both the nerve-ending fraction and slice preparation correlated with the occupancy of a single low-affinity form of the muscarinic receptor."( Differential stimulation of inositol phospholipid turnover in brain by analogs of oxotremorine.
Bartus, RT; Figueiredo, JC; Fisher, SK, 1984
)
0.75
" While the dose-response curves for the antipsychotic drugs were parallel, had steep slopes and similar maxima, the curves for morphine and oxotremorine were irregularly shaped but the curve for morphine in the TO had some similarity to that of the antipsychotic drugs."( The differential effects of morphine, oxotremorine and antipsychotic drugs on DOPAC concentrations in rat brain.
Stanley, M; Wilk, S, 1980
)
0.73
" Thus, the dose-response curve shows an U-shaped form."( The impairment of retention induced by beta-endorphin in mice may be mediated by a reduction of central cholinergic activity.
Baratti, CM; Introini, IB, 1984
)
0.27
" Tremorolytic potency (ED50) was calculated from dose-response curves."( Cholecystokinin octapeptide (CCK-8), ceruletide and analogues of ceruletide: effects on tremors induced by oxotremorine, harmine and ibogaine. A comparison with prolyl-leucylglycine amide (MIF), anti-Parkinsonian drugs and clonazepam.
Zetler, G, 1983
)
0.48
" Second, the dose-response relationships for the cyclic AMP and PhI responses differ; the half-maximal concentrations of carbachol needed to inhibit cAMP accumulation and stimulate PhI hydrolysis are 2 X 10(-7) and 2 X 10(-5) M, respectively."( Agonists differentiate muscarinic receptors that inhibit cyclic AMP formation from those that stimulate phosphoinositide metabolism.
Brown, JH; Brown, SL, 1984
)
0.27
" Incubation of the isolated guinea pig ileum for 30 min with BM 123 at 20 microM and 2 microM caused 94% and 48% receptor alkylation, respectively, as calculated from the shift in the agonist dose-response curve."( The conversion of 2-chloroalkylamine analogues of oxotremorine to aziridinium ions and their interactions with muscarinic receptors in the guinea pig ileum.
Dahlbom, R; Ehlert, FJ; Jenden, DJ; Resul, B; Ringdahl, B, 1984
)
0.52
" Cumulative dose-response curves were constructed for the effects of oxotremorine on body temperature and rotarod performance by administering sequential injections to individual animals."( Quantitation of tolerance development after chronic oxotremorine treatment.
Artman, LD; Collins, AC; Marks, MJ, 1983
)
0.75
" The dose-response curve was an inverted U in this range of dose."( Possible interaction between central cholinergic muscarinic and opioid peptidergic systems during memory consolidation in mice.
Baratti, CM; Huygens, P; Introini, IB, 1984
)
0.27
" The method used involved analysis of dose-response data before and after fractional inactivation of receptors with propylbenzilylcholine mustard."( Muscarinic receptor occupation and receptor activation in the guinea-pig ileum by some acetamides related to oxotremorine.
Ringdahl, B, 1984
)
0.48
" after 30 min pretreatment produced a significant and parallel shift in OTMN's analgesic dose-response line, assessed by the hot plate test (55 degrees C)."( Some observations on the effects of enantiomers of two benzomorphan narcotic antagonists and atropine on analgesia, tremor and hypothermia produced by oxotremorine.
Ben-Sreti, MM; Sewell, RD; Upton, N, 1982
)
0.46
" Dose-response curves for selected agents showed that maximal stimulation of synthesis was to 136-140% of the value without an antagonist."( Evidence for the pharmacological similarity between the central presynaptic muscarinic autoreceptor and postsynaptic muscarinic receptors.
Bowen, DM; Marek, KL, 1982
)
0.26
" Chronic but not acute administration of DMI potentiated the locomotor response to d-amphetamine within a narrow dosage range."( Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine.
Fibiger, HC; Spyraki, C, 1981
)
0.26
" Tremor was not observed during this period; however, motor slowing and working memory impairment persisted throughout the dosing period in all treated groups."( Repeated inhibition of cholinesterase by chlorpyrifos in rats: behavioral, neurochemical and pharmacological indices of tolerance.
Bushnell, PJ; Kelly, KL; Ward, TR, 1994
)
0.29
" The muscarinic antagonists, pirenzepine and AF-DX 116, shifted the dose-response curve for the muscarine INs to the right in a parallel manner."( Mechanism of activation of nonselective cation channels by putative M4 muscarinic receptor in guinea-pig chromaffin cells.
Imanaga, I; Inoue, M, 1995
)
0.29
" Nicotine enhanced release, with a bell-shaped dose-response curve."( Lesion with the neurotoxin AF64A alters hippocampal cholinergic receptor function.
Potter, PE; Thorne, B, 1995
)
0.29
" Oxotremorine generated dose-response curves that were similar in both the circular and longitudinal vectors and intermediate to those previously reported for carbachol and aceclidine."( The effect of muscarinic agonists and selective receptor subtype antagonists on the contractile response of the isolated rhesus monkey ciliary muscle.
Gabelt, BT; Kaufman, PL; Poyer, JF, 1994
)
1.2
" However, in 22MO rats, the behavioral dose-response curve for scopolamine was shifted towards greater sensitivity."( Cholinergic manipulations in the medial septal area: age-related effects on working memory and hippocampal electrophysiology.
Givens, B; Markowska, AL; Olton, DS, 1995
)
0.29
"25 microM), revealing a separation of the dose-response relationships."( A comparison between muscarinic receptor occupancy, inositol 1,4,5-trisphosphate accumulation and Ca2+ mobilization in permeabilized SH-SY5Y neuroblastoma cells.
Nahorski, SR; Safrany, ST, 1994
)
0.29
" The mean IC50 values for ACh and oxotremorine methiodide (oxo-M), obtained from non-cumulative dose-response curves, were 204 and 363 nM respectively."( M2 muscarinic receptor-mediated inhibition of the Ca2+ current in rat magnocellular cholinergic basal forebrain neurones.
Allen, TG; Brown, DA, 1993
)
0.57
"1 microM), shifted the dose-response curve for muscarine-induced adrenaline secretion to the right."( Muscarinic receptor subtypes mediating catecholamine secretion and increase in intracellular Ca2+ concentration in adrenal chromaffin cells of the guinea pig.
Asano, T; Ito, S; Nakazato, Y; Ohta, T; Otsuguro, K, 1995
)
0.29
" This model closely simulated the time courses of onset and recovery of inhibition and reinhibition, as well as the dose-response curve for inhibition of Ca2+ channels by NE."( Speed of Ca2+ channel modulation by neurotransmitters in rat sympathetic neurons.
Hille, B; Shapiro, MS; Zhou, J, 1997
)
0.3
" (-)-Rolipram produced a biphasic dose-response and (+/-)-rolipram produced a broad dose-response."( Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats.
Egawa, T; Fujiwara, M; Iwasaki, K; Matsumoto, Y; Mishima, K, 1997
)
0.3
" Sigmoid dose-response curves were plotted, and the IC50s were calculated."( Comparison of the effects of M1 and M2 muscarinic receptor activation in the absence of GABAergic inhibition in immature rat hippocampal CA3 area.
Beaucher, J; Harnois, C; Psarropoulou, C, 1998
)
0.3
" The dose-response parameters of recombinant mouse adult neuromuscular acetylcholine receptor channels (nAChR) activated by carbamylcholine, nicotine, muscarine and oxotremorine were measured."( Activation of muscle nicotinic acetylcholine receptor channels by nicotinic and muscarinic agonists.
Akk, G; Auerbach, A, 1999
)
0.5
" The first experiment examined the dose-response effects of oxotremorine on the number of vocalizations and acoustic parameters of 10-, 15-, and 17-day-old rat pups."( The effect of cholinergic stimulation on rat pup ultrasonic vocalizations.
Brudzynski, S; Callahan, M; Daigle, A; Kehoe, P; Mallinson, K, 2001
)
0.55
" The present experiments were performed in order to obtain more information on the relationship between the OX-induced sensitization to AMPH and the OX dose and dosing regime (single or repeated), and to find out whether the environment associated with the acute effects of OX could affect the response to AMPH."( Alteration in behavioral sensitivity to amphetamine after treatment with oxotremorine. Effect of dose and test environment.
Gralewicz, S; Lutz, P; Tomas, T; Wiaderna, D, 2003
)
0.55
" Such a hyposensitivity did not develop after a single or multiple (at short intervals) dosing with oxotremorine (OXO), a direct muscarinic agonist, which suggests that it was not mediated by muscarinic receptors."( Behavioral sensitivity to amphetamine or scopolamine after acute administration of nicotine in the rat.
Gralewicz, S; Lutz, P, 2005
)
0.54
" A shift to the right of the physostigmine dose-response curve was obtained after anti-type 2 IP3R2 and anti-type 3 IP3R treatments."( Knockdown of the type 2 and 3 inositol 1,4,5-trisphosphate receptors suppresses muscarinic antinociception in mice.
Bartolini, A; Galeotti, N; Ghelardini, C; Quattrone, A; Vivoli, E, 2007
)
0.34
" Selected "hits" were subjected to further dose-response testing, and their ability to modulate expression of UPR and oxidative stress markers was assessed by RT-PCR, Western blot, and measurement of protein carbonyl and 8-hydroxydeoxyguanosine (8-OHdG) adducts in immortalized human corneal endothelial cells (iHCECs)."( Screening and Characterization of Drugs That Protect Corneal Endothelial Cells Against Unfolded Protein Response and Oxidative Stress.
Berlinicke, CA; Jun, AS; Jurkunas, U; Kim, EC; Toyono, T; Usui, T; Zack, DJ, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-alkylpyrrolidine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (26)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency63.09570.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.00090.004023.8416100.0000AID485290
LuciferasePhotinus pyralis (common eastern firefly)Potency25.11890.007215.758889.3584AID411
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency7.94330.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.15850.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency1.49770.00636.904339.8107AID883
D(1A) dopamine receptorHomo sapiens (human)Potency2.90910.02245.944922.3872AID488982
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency22.38720.050127.073689.1251AID588590
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency1.49770.00638.235039.8107AID883
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency8.49210.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)0.40000.00001.23267.7930AID140947
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki2.75570.00000.690210.0000AID142530; AID142532; AID1482282; AID1482283; AID1482285; AID1648530; AID1648531; AID1648532; AID322941
Muscarinic acetylcholine receptor M4Homo sapiens (human)IC50 (µMol)5.00000.00001.15467.5858AID142022
Muscarinic acetylcholine receptor M4Homo sapiens (human)Ki0.08070.00000.79519.1201AID141886; AID141887
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)IC50 (µMol)2.32100.00052.773925.1700AID141540; AID141543; AID141544; AID141554; AID141667; AID141669; AID141675; AID141676; AID142022
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Ki9.03120.00010.579710.0000AID141722; AID142216; AID142217; AID142223; AID142224; AID142343; AID142345; AID142346; AID142347
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)IC50 (µMol)2.72610.00052.891925.1700AID141540; AID141543; AID141544; AID141667; AID141669; AID141675; AID141676; AID142022
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)Ki179,420,715,894.09790.00011.48339.1400AID101702; AID141739; AID142216; AID142217; AID142223; AID142224; AID142343; AID142345; AID142346; AID142347
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)IC50 (µMol)2.72610.00052.747825.1700AID141540; AID141543; AID141544; AID141667; AID141669; AID141675; AID141676; AID142022
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)Ki9.76750.00010.68688.2600AID142216; AID142217; AID142223; AID142224; AID142343; AID142345; AID142346; AID142347
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)IC50 (µMol)2.72610.00052.780225.1700AID141540; AID141543; AID141544; AID141667; AID141669; AID141675; AID141676; AID142022
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)Ki9.76750.00010.66618.2600AID142216; AID142217; AID142223; AID142224; AID142343; AID142345; AID142346; AID142347
Muscarinic acetylcholine receptor M5Homo sapiens (human)IC50 (µMol)8.00000.00010.99178.0000AID142281
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)IC50 (µMol)2.72610.00053.314249.5000AID141540; AID141543; AID141544; AID141667; AID141669; AID141675; AID141676; AID142022
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)Ki334,124,652,961.42480.00010.58908.2600AID101702; AID101704; AID140936; AID142216; AID142217; AID142223; AID142224; AID142343; AID142345; AID142346; AID142347
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)12.03410.00001.403910.0000AID141040; AID141041; AID141973
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki0.00910.00000.59729.1201AID141179; AID322940
Muscarinic acetylcholine receptor DM1Drosophila melanogaster (fruit fly)Ki20.45000.00051.42495.2000AID1090601; AID1090602
Muscarinic acetylcholine receptor M3Homo sapiens (human)IC50 (µMol)17.00000.00011.01049.9280AID141745
Muscarinic acetylcholine receptorCavia porcellus (domestic guinea pig)Ki2,505,934,897,152.08000.00010.61203.8019AID101702; AID140936
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
MCOLN3 proteinHomo sapiens (human)EC50 (µMol)29.90000.78103.16035.9900AID1562
transient receptor potential cation channel, subfamily N, member 1Danio rerio (zebrafish)EC50 (µMol)29.90001.47003.45505.4400AID1682
Muscarinic acetylcholine receptor M2Homo sapiens (human)EC50 (µMol)0.01900.00000.737810.0000AID142379
Muscarinic acetylcholine receptor M2Homo sapiens (human)Kd0.93000.00050.16230.9300AID141146
Muscarinic acetylcholine receptor M4Homo sapiens (human)EC50 (µMol)0.01870.00570.84656.6069AID141868; AID1510619; AID1510620
Muscarinic acetylcholine receptor M4Homo sapiens (human)Kd0.93000.00090.18830.9300AID141146
Muscarinic acetylcholine receptor M5Homo sapiens (human)EC50 (µMol)0.05500.05501.957010.0000AID142145
Muscarinic acetylcholine receptor M5Homo sapiens (human)Kd0.93000.00090.18830.9300AID141146
Muscarinic acetylcholine receptor M1Homo sapiens (human)EC50 (µMol)0.19580.00161.304310.0000AID1193905; AID141037
Muscarinic acetylcholine receptor M1Homo sapiens (human)Kd0.93000.00090.98292.6915AID141146
Muscarinic acetylcholine receptor M1Mus musculus (house mouse)EC50 (µMol)0.27000.27004.29006.9000AID141319
Muscarinic acetylcholine receptor M3Homo sapiens (human)EC50 (µMol)0.21000.00040.99355.9000AID141345
Muscarinic acetylcholine receptor M3Homo sapiens (human)Kd0.93000.00090.18830.9300AID141146
Mineralocorticoid receptorRattus norvegicus (Norway rat)EC50 (µMol)29.90005.44005.44005.4400AID1682
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (39)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (208)

Assay IDTitleYearJournalArticle
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))1997Molecular pharmacology, Jul, Volume: 52, Issue:1
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
AID1345189Rat M1 receptor (Acetylcholine receptors (muscarinic))1989The Journal of pharmacology and experimental therapeutics, Feb, Volume: 248, Issue:2
Pharmacological characterization of the M1 muscarinic receptors expressed in murine fibroblast B82 cells.
AID1345364Rat M2 receptor (Acetylcholine receptors (muscarinic))1998The Journal of pharmacology and experimental therapeutics, Feb, Volume: 284, Issue:2
Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))1997Molecular pharmacology, Jul, Volume: 52, Issue:1
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1997Molecular pharmacology, Jul, Volume: 52, Issue:1
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1998The Journal of pharmacology and experimental therapeutics, Feb, Volume: 284, Issue:2
Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))1997Molecular pharmacology, Jul, Volume: 52, Issue:1
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID141066Maximum contractile response relative to carbachol (E max) in guinea pig ileum as muscarinic acetylcholine receptor M3 agonistic/antagonistic activity1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide.
AID141739Binding affinity to Muscarinic acetylcholine receptor M3 by measuring its ability to displace [3H]N-methylscopolamine binding in rat submandibulary gland1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Synthesis and pharmacological characterization of O-alkynyloximes of tropinone and N-methylpiperidinone as muscarinic agonists.
AID141665In vitro binding affinity to the Muscarinic acetylcholine receptor by displacing [3H]-QNB from the rat heart tissues1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID231956Ratio of displacement of NMS and Oxo-M from muscarinic receptor M12001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
Synthesis and In vitro binding affinities of 1-azabicyclic compounds as muscarinic ligands.
AID141037In Vitro evaluation activity at the cloned Human Muscarinic acetylcholine receptor M1 determined by receptor selection and amplification technology (R-SAT)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID9457The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Muscarinic receptor binding and activation of second messengers by substituted N-methyl-N-[4-(1-azacycloalkyl)-2-butynyl]acetamides.
AID231030Muscarinic 2 receptor agonistic activity was determined as the selectivity ratio of Ki against [3H]QNB+ Gpp(NH)p to that of [3H]QNB1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Chemical and biochemical studies of 2-propynylpyrrolidine derivatives. Restricted-rotation analogues of N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM-5).
AID141041Ability to displace [3H]oxotremorine from Muscarinic acetylcholine receptor M1 expressed in CHO cells.2001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
Synthesis and In vitro binding affinities of 1-azabicyclic compounds as muscarinic ligands.
AID142379In Vitro activity at the cloned Human Muscarinic acetylcholine receptor M2 determined by receptor selection and amplification technology (R-SAT).1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID114480Central muscarinic activity administered intraperitoneally to mice, expressed as hypothermia1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
5-Methyl-2-pyrrolidone analogues of oxotremorine as selective muscarinic agonists.
AID142530Inhibition of [3H]- oxotremorine-M binding to human Muscarinic acetylcholine receptor M2 expressed in CHO cell membranes2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID71804Tested for its effect on contraction of frog rectus abdominis muscle, expressed as equipotent molar ratio relative to carbamylcholine.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Stereoselectivity of muscarinic receptors in vivo and in vitro for oxotremorine analogues. N-[4-(tertiary amino)-2-butynyl]-5-methyl-2-pyrrolidones.
AID141319Tested against Muscarinic acetylcholine receptor M1 expressed in A9 L cell line1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID140938Intrinsic activity against Muscarinic acetylcholine receptor M2 in rat striatum (activity expressed as % response of that produced by carbachol)1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Synthesis and in vitro characterization of novel amino terminally modified oxotremorine derivatives for brain muscarinic receptors.
AID141198Relative efficacies determined with oxotremorine as the reference in guinea pig ileum, as a measure of muscarinic acetylcholine receptor M3 agonistic activity1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide.
AID131227Muscarinic activity tested by measuring salivation in mice after ip administration1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Tertiary 3- and 4-haloalkylamine analogues of oxotremorine as prodrugs of potent muscarinic agonists.
AID131229Muscarinic activity tested by measuring tremor in mice after ip administration1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Tertiary 3- and 4-haloalkylamine analogues of oxotremorine as prodrugs of potent muscarinic agonists.
AID142660Ratio of Ki of [3H]-NMS binding to that of [3H]OXO-M binding.1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Synthesis and cholinergic properties of N-aryl-2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethylamino analogs of ranitidine.
AID112391Tremor after subcutaneous administration in mice was determined1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity.
AID141543In vitro inhibition of [3H]OXO-M binding to Muscarinic receptor from rat cortical homogenates1992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives.
AID114184Effective dose against, administration in mice; Not tested1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID141887Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor M4 expressed in CHO cell membranes2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID141040Ability to displace [3H]N-methylscopolamine from Muscarinic acetylcholine receptor M1 expressed in CHO cells.2001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
Synthesis and In vitro binding affinities of 1-azabicyclic compounds as muscarinic ligands.
AID1193908Agonist activity at human m2 muscarinic acetylcholine receptor expressed in HEK293 cells by calcium mobilization assay at 10 microM by FLIPR assay relative to 100 nM acetylcholine response2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis and biological evaluation of isoxazoline derivatives as potent M₁ muscarinic acetylcholine receptor agonists.
AID141436Maximum stimulation at Muscarinic acetylcholine receptor M1 expressed in A9 L cells1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID1193909Agonist activity at human m3 muscarinic acetylcholine receptor expressed in HEK293 cells by calcium mobilization assay at 10 microM by FLIPR assay relative to 100 nM acetylcholine response2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis and biological evaluation of isoxazoline derivatives as potent M₁ muscarinic acetylcholine receptor agonists.
AID141136Tested for agonist activity at Muscarinic acetylcholine receptor in guinea pig ileum1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Stereoselectivity of muscarinic receptors in vivo and in vitro for oxotremorine analogues. N-[4-(tertiary amino)-2-butynyl]-5-methyl-2-pyrrolidones.
AID112961Compound was tested for its ability to induce tremors in mice subcutaneous administration1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID176362Concentration required to relax phenylephrine-precontracted aortic rings by 50% in endothelium intact rat aorta1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Synthesis and pharmacological characterization of O-alkynyloximes of tropinone and N-methylpiperidinone as muscarinic agonists.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID101700Binding affinity at [3H]CD radiolabeled muscarinic M2 receptor in rat cortex.1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
The synthesis and biochemical pharmacology of enantiomerically pure methylated oxotremorine derivatives.
AID142346Inhibition of [3H]- oxotremorine-M binding to Muscarinic acetylcholine receptor of rat heart membranes.2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID141530In vitro ability to displace [3H]oxotremorine-M (OXO-M) from rat cerebral cortex muscarinic acetylcholine receptor1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands.
AID141868In Vitro activity at the cloned Human Muscarinic acetylcholine receptor M4 determined by receptor selection and amplification technology (R-SAT)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID193266Neuronal postsynaptic muscarinic activity was measured relative to muscurine (100%)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID230876Ratio of affinity versus antagonist [3H]-QNB divided by affinity versus agonist [3H]OXO-M2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID78847Tested for agonist activity at muscarinic receptor in guinea pig ileum, expressed as equipotent molar ratio relative to carbamylcholine.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Stereoselectivity of muscarinic receptors in vivo and in vitro for oxotremorine analogues. N-[4-(tertiary amino)-2-butynyl]-5-methyl-2-pyrrolidones.
AID101734Peripheral postsynaptic muscarinic activity by contraction of the guinea pig ileum.1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID228728Ratio of the binding affinities against muscarinic M2 and muscarinic M1 receptors.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID66345Agonism of endothelin A receptor was determined as maximal rate of vascular endothelium-dependent relaxation at the concentration of 10E-5 M/L2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Discovering selective agonists of endothelial target for acetylcholine (ETA) via diversity-guided pharmacophore simplification and simulation.
AID142345Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor of rat cerebral cortical membranes2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID169186Conditioned avoidance responding in rat after subcutaneous administration (0.3 mg/kg); expressed as avoidance response/response failure; 24/631998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity.
AID1648532Displacement of 4-(2-((1E,3E)-5-((E)-1-(6-((3,5-Bis((2-(3-(1-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)-1H-imidazol-4-yl)propanamido)ethyl)carbamoyl)benzyl)amino)-6-oxohexyl)-3,3-dimethyl-5-sulfoindo2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Red-Emitting Dibenzodiazepinone Derivatives as Fluorescent Dualsteric Probes for the Muscarinic Acetylcholine M
AID77701Maximal contractile response as a percentage of that elicited by carbachol.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Beta-lactam analogues of oxotremorine. 3- and 4-methyl-substituted 2-azetidinones.
AID141959Intrinsic activity against Muscarinic acetylcholine receptor M1 in rat cortex (activity expressed as % response of that produced by carbachol)1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Synthesis and in vitro characterization of novel amino terminally modified oxotremorine derivatives for brain muscarinic receptors.
AID1090601Displacement of [3H]QNB from Drosophila melanogaster mAChR by scintillation counting2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID142340In vitro inhibition of binding of (-)-[3H]-NMS to Muscarinic acetylcholine receptor of rat cerebral cortex was determined1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Beta-lactam analogues of oxotremorine. 3- and 4-methyl-substituted 2-azetidinones.
AID118336Antagonistic activity against Scopolamine induced behavioral deficits in mice at dose 0.31 mg/kg sc; Not tested1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID113180In vivo antinociceptive activity was measured using mouse grid shock (MGS) assay in mice upon subcutaneous administration1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID140936Binding affinity to Muscarinic acetylcholine receptor M2 by measuring its ability to displace [3H]N-methylscopolamine binding in rat heart1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Synthesis and pharmacological characterization of O-alkynyloximes of tropinone and N-methylpiperidinone as muscarinic agonists.
AID142656Ability to displace [3H]methylscopolamine ([3H]NMS) from mouse cerebral cortex1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Synthesis and cholinergic properties of N-aryl-2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethylamino analogs of ranitidine.
AID142145In Vitro activity at the cloned Human Muscarinic acetylcholine receptor M5 determined by receptor selection and amplification technology (R-SAT)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID131228Muscarinic activity tested by measuring salivation in mice after iv administration1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Tertiary 3- and 4-haloalkylamine analogues of oxotremorine as prodrugs of potent muscarinic agonists.
AID1510619Agonist activity at human Muscarinic acetylcholine receptor M4 expressed in HEK cells co-expressing Glosensor construct assessed as decrease in isoproterenol-induced cAMP accumulation incubated for 7 mins in presence of isoproterenol by Glosensor cAMP rea2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Discovery of Selective M4 Muscarinic Acetylcholine Receptor Agonists with Novel Carbamate Isosteres.
AID79213Relative efficacy calculated from KA and ED50 values1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Stereoselectivity of muscarinic receptors in vivo and in vitro for oxotremorine analogues. N-[4-(tertiary amino)-2-butynyl]-5-methyl-2-pyrrolidones.
AID112393Tremorigenic effects were assessed in mice after subcutaneous administration of the compound1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
AID230678Ratio of [3H]QNB+GppNHp/[3H]-QNB1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
The synthesis and biochemical pharmacology of enantiomerically pure methylated oxotremorine derivatives.
AID101703Binding affinity at [3H]QNB radiolabeled muscarinic M2 receptor in rat cortex.1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
The synthesis and biochemical pharmacology of enantiomerically pure methylated oxotremorine derivatives.
AID142343The binding affinity was measured as inhibition of binding of [3H]- oxotremorine-M to muscarinic acetylcholine receptor in rat cerebral cortical membranes.2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID79209Percent occupancy for 50% response calculated from (100 x ED50)/(KA+ED50).1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Stereoselectivity of muscarinic receptors in vivo and in vitro for oxotremorine analogues. N-[4-(tertiary amino)-2-butynyl]-5-methyl-2-pyrrolidones.
AID142223Binding affinity to muscarinic acetylcholine receptor was determined in presence of [3H]OXO-M radioligand (in vitro)1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Cholinergic activity of acetylenic imidazoles and related compounds.
AID231028Muscarinic 1 receptor agonistic activity as the selectivity ratio of Ki against [3H]-QNB to that of [3H]PZ1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Chemical and biochemical studies of 2-propynylpyrrolidine derivatives. Restricted-rotation analogues of N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM-5).
AID178179Inhibition of conditioned avoidance response in rat following s.c. administration.1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity.
AID142213Binding activity to the muscarinic acetylcholine receptor in rat cortex, assayed using [3H]CD as a radioligand.1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Chemical and biochemical studies of 2-propynylpyrrolidine derivatives. Restricted-rotation analogues of N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM-5).
AID142894The agonist ratio as the ratio of Ki against [3H]QNB to that of [3H]-CD1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Chemical and biochemical studies of 2-propynylpyrrolidine derivatives. Restricted-rotation analogues of N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM-5).
AID142214Binding activity to the muscarinic acetylcholine receptor in rat cortex, assayed using [3H]PZ as a radioligand.1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Chemical and biochemical studies of 2-propynylpyrrolidine derivatives. Restricted-rotation analogues of N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM-5).
AID142658Ability to displace [3H]oxotremorine ([3H]-OXO-M) from mouse cerebral cortex1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Synthesis and cholinergic properties of N-aryl-2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethylamino analogs of ranitidine.
AID142022Compound was evaluated for its ability to displace [3H]- N-methyl-scopolamine ([3H]-NMS) binding to cloned CHO cell lines expressing Muscarinic acetylcholine receptor M41998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID1193905Agonist activity at human m1 muscarinic acetylcholine receptor expressed in HEK293 cells assessed as calcium mobilization by FLIPR assay2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis and biological evaluation of isoxazoline derivatives as potent M₁ muscarinic acetylcholine receptor agonists.
AID141353Inhibition of binding of [3H]- quinuclidinyl benzilate to Muscarinic acetylcholine receptor M3 in membranes of CHO cells at 100 uM compound concentration2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID55204The percent inhibition of cyclic AMP(cAMP) formation in NG108-15 cells at 100 uM.1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Muscarinic receptor binding and activation of second messengers by substituted N-methyl-N-[4-(1-azacycloalkyl)-2-butynyl]acetamides.
AID1648530Displacement of 4-(2-((1E,3E)-5-((E)-3,3-Dimethyl-1-(6-oxo-6-((2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-1-yl)ethyl)amino)hexyl)-5-sulfoindolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimet2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Red-Emitting Dibenzodiazepinone Derivatives as Fluorescent Dualsteric Probes for the Muscarinic Acetylcholine M
AID1482283Displacement of [3H]UR-AP060 from human muscarinic acetylcholine receptor M2 expressed in CHOK9 cell homogenate after 3 hrs by liquid scintillation counting assay2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Radiolabeled Dibenzodiazepinone-Type Antagonists Give Evidence of Dualsteric Binding at the M
AID1090602Displacement of [3H]AF-DX 384 from Drosophila melanogaster mAChR by scintillation counting2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID27359Acute toxicity in mice1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Stereoselectivity of muscarinic receptors in vivo and in vitro for oxotremorine analogues. N-[4-(tertiary amino)-2-butynyl]-5-methyl-2-pyrrolidones.
AID230877Relative displacement of antagonist [3H]QNB and agonist [3H]-OXO-M from rat heart membranes2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID114040Muscarinic activity administered intraperitoneally to mice, expressed as salivation1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
5-Methyl-2-pyrrolidone analogues of oxotremorine as selective muscarinic agonists.
AID141667Inhibition of [3H]quinuclidinyl benzilate (QNB) binding from rat forebrain membranes in the absence of Zn1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID1510620Positive allosteric modulatory activity at human Muscarinic acetylcholine receptor M4 expressed in HEK cells co-expressing Glosensor construct assessed as as increase in acteylcholine-induced cAMP accumulation incubated for 7 mins in presence of isoproter2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Discovery of Selective M4 Muscarinic Acetylcholine Receptor Agonists with Novel Carbamate Isosteres.
AID73903Muscarinic activity in isolated guinea pig ileum1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Tertiary 3- and 4-haloalkylamine analogues of oxotremorine as prodrugs of potent muscarinic agonists.
AID141057Inhibition of binding of [3H]- quinuclidinyl benzilate to Muscarinic acetylcholine receptor M1 in membranes of CHO cells at 100 uM compound concentration2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID1193911Agonist activity at human m5 muscarinic acetylcholine receptor expressed in HEK293 cells by calcium mobilization assay at 10 microM by FLIPR assay relative to 100 nM acetylcholine response2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis and biological evaluation of isoxazoline derivatives as potent M₁ muscarinic acetylcholine receptor agonists.
AID1482285Displacement of [3H]NMS from human muscarinic acetylcholine receptor M22017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Radiolabeled Dibenzodiazepinone-Type Antagonists Give Evidence of Dualsteric Binding at the M
AID141533In vitro ability to displace [3H]quinuclidinyl benzilate (QNB) from rat cerebral cortex muscarinic acetylcholine receptor1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands.
AID141663In vitro binding affinity to the Muscarinic acetylcholine receptor by displacing [3H]PZ from the rat brain tissues1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID142347Inhibition of [3H]- quinuclidinyl benzilate binding to Muscarinic acetylcholine receptor of rat heart membranes.2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID141664In vitro binding affinity to the Muscarinic acetylcholine receptor by displacing [3H]QNB from the rat brain tissues1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID141063Agonism of Muscarinic acetylcholine receptor M3 was determined as maximal contraction rate of isolated guinea pig ileum; 30-50%2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Discovering selective agonists of endothelial target for acetylcholine (ETA) via diversity-guided pharmacophore simplification and simulation.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID231701Relative [3H]QNB and [3H]-CD binding to muscarinic M2 receptor1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
The synthesis and biochemical pharmacology of enantiomerically pure methylated oxotremorine derivatives.
AID1648531Displacement of 4-(2-((1E,3E)-5-((E)-3,3-Dimethyl-1-(6-oxo-6-((2-(3-(1-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)-1H-imidazol-4-yl)propanamido)ethyl)-amino)hexyl)-5-sulfoindolin-2-ylidene)penta-1,3-d2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Red-Emitting Dibenzodiazepinone Derivatives as Fluorescent Dualsteric Probes for the Muscarinic Acetylcholine M
AID1482282Displacement of [3H]UNSW-MK259 from human muscarinic acetylcholine receptor M2 expressed in CHOK9 cells after 3 hrs by liquid scintillation counting assay2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Radiolabeled Dibenzodiazepinone-Type Antagonists Give Evidence of Dualsteric Binding at the M
AID141745Compound was evaluated for its ability to displace [3H]N-methylscopolamine ([3H]NMS) binding to cloned CHO cell lines expressing Muscarinic acetylcholine receptor M31998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID197332Neuronal postsynaptic muscarinic activity was measured by firing rate of the rat hippocampal CA1 neurons in M1 model1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID114232Salivation after subcutaneous administration in mice1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity.
AID141669Inhibition of [3H]quinuclidinyl benzilate (QNB) binding from rat forebrain membranes in the presence of Zn1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID232983Relative efficacy determined by agonist index.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID140947Compound was evaluated for its ability to displace [3H]- N-methyl-scopolamine ([3H]NMS) binding to cloned CHO cell lines expressing Muscarinic acetylcholine receptor M21998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID141146Dissociation constant of the drug-Muscarinic acetylcholine receptor complex.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Beta-lactam analogues of oxotremorine. 3- and 4-methyl-substituted 2-azetidinones.
AID31797Compound was evaluated for the binding affinity by displacing [3H]oxotremorine from mouse cerebral cortex tissue.1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Synthesis and cholinergic properties of bis[[(dimethylamino)methyl]furanyl] analogues of ranitidine.
AID141065Muscarinic acetylcholine receptor M3 agonistic/antagonistic activity in guinea pig ileum1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide.
AID230976Ratio of the effectivie concentrations against muscarinic M2 and muscarinic M1 receptors.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID113327ED50 value as cholinergic agonist by measuring salivation in mice (in vivo)1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Cholinergic activity of acetylenic imidazoles and related compounds.
AID112706Dose producing 50% fall in rhythmic slow wave activity in mouse1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
AID101732Peripheral postsynaptic muscarinic activity was measured relative to muscarine (100%)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID142281Compound was evaluated for its ability to displace [3H]- N-methyl-scopolamine ([3H]NMS) binding to cloned CHO cell lines expressing Muscarinic acetylcholine receptor M51998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID141848Ratio of ability to displace pirenzpine compared to ability to displace CD (non-selective muscarinic agonist).1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID1193906Agonist activity at human m1 muscarinic acetylcholine receptor expressed in HEK293 cells by calcium mobilization assay at 10 microM by FLIPR assay relative to 100 nM acetylcholine response2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis and biological evaluation of isoxazoline derivatives as potent M₁ muscarinic acetylcholine receptor agonists.
AID141179Inhibition of [3H]- oxotremorine-M binding to human Muscarinic acetylcholine receptor M1 expressed in CHO cell membranes2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID112960Compound was tested for its ability to induce salivation in mice upon subcutaneous administration1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID142501In vitro inhibition of [3H]Oxo-Mas binding to M1 and M4 receptors in rat brain homogenate.1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity.
AID229750Ratio of inhibition of QNB to OXO-M binding to Muscarinic receptor1992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives.
AID141477The binding affinity was measured as inhibition of binding of [3H]- oxotremorine-M to Muscarinic acetylcholine receptor M3 in membranes of CHO cells; ND means no data2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID128496Analgesic activity was measured by tail flick assay1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Tertiary 3- and 4-haloalkylamine analogues of oxotremorine as prodrugs of potent muscarinic agonists.
AID141540Ability to displace [3H]cis--2-methyl-5-((dimethylamino)methyl)-1,3-di oxolane from muscarinic acetylcholine receptor in rat cortical tissue.1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID32094Inhibitory activity against acetylcholinesterase in rat striatal preparation1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID142355Ratio of Compound (IC50(nM) of QNB/ IC50(nM) of OXO-M)1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands.
AID110673Extrapyramidal effects was assessed from the dose producing tremors1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
AID113328ED50 value as cholinergic agonist by measuring tremors in mice (in vivo)1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Cholinergic activity of acetylenic imidazoles and related compounds.
AID141675Inhibition of radioligand [3H]QNB binding (competitive inhibition) to muscarinic acetylcholine receptor in the rat forebrain in the absence of zinc1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Substituted (pyrroloamino)pyridines: potential agents for the treatment of Alzheimer's disease.
AID113326ED50 value as cholinergic agonism by measuring lacrimation in mice (in vivo)1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Cholinergic activity of acetylenic imidazoles and related compounds.
AID322940Binding affinity to human cloned muscarinic M1 receptor expressed in CHO cells2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Docking analyses on human muscarinic receptors: unveiling the subtypes peculiarities in agonists binding.
AID141554Ability to displace [3H]pirenzepine (pir) from muscarinic acetylcholine receptor M1 in rat cortical tissue.1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID1193910Agonist activity at human m4 muscarinic acetylcholine receptor expressed in HEK293 cells by calcium mobilization assay at 10 microM by FLIPR assay relative to 100 nM acetylcholine response2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Synthesis and biological evaluation of isoxazoline derivatives as potent M₁ muscarinic acetylcholine receptor agonists.
AID31796Compound was evaluated for the binding affinity by displacing [3H]methylscopolamine [3H]NMS from mouse cerebral cortex tissue.1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Synthesis and cholinergic properties of bis[[(dimethylamino)methyl]furanyl] analogues of ranitidine.
AID31800NMS/OXO-M values are calculated from the ratio of the respective apparent Ki values1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Synthesis and cholinergic properties of bis[[(dimethylamino)methyl]furanyl] analogues of ranitidine.
AID101704Binding affinity at [3H]QNB radiolabeled muscarinic M2 receptor in rat heart.1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
The synthesis and biochemical pharmacology of enantiomerically pure methylated oxotremorine derivatives.
AID232956Inhibitory selectivity for Muscarinic receptors M3 and M11998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Synthesis and pharmacological characterization of O-alkynyloximes of tropinone and N-methylpiperidinone as muscarinic agonists.
AID141544In vitro inhibition of [3H]QNB binding to Muscarinic receptor from rat cortical homogenates1992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives.
AID113681Inhibition of apomorphine-induced climbing following s.c. administration in mice.1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity.
AID141661In vitro binding affinity to the Muscarinic acetylcholine receptor by displacing [3H]- Oxo-M from the rat brain tissues1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID141676Inhibition of radioligand [3H]QNB binding to muscarinic acetylcholine receptor in the rat forebrain in the presence of zinc1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Substituted (pyrroloamino)pyridines: potential agents for the treatment of Alzheimer's disease.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID104025Binding affinity at [3H]PZ radiolabeled muscarinic M1 receptor in rat cortex.1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
The synthesis and biochemical pharmacology of enantiomerically pure methylated oxotremorine derivatives.
AID9459Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Muscarinic receptor binding and activation of second messengers by substituted N-methyl-N-[4-(1-azacycloalkyl)-2-butynyl]acetamides.
AID193265Central postsynaptic muscarinic activity was measured relative to muscurine (100%)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID142949Compound was evaluated for its binding affinity towards muscarinic acetylcholine receptor M2 in rat brainstem1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Synthesis and in vitro characterization of novel amino terminally modified oxotremorine derivatives for brain muscarinic receptors.
AID131232Muscarinic activity tested by measuring tremor in mice after iv administration1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Tertiary 3- and 4-haloalkylamine analogues of oxotremorine as prodrugs of potent muscarinic agonists.
AID232606Ratio of IC50 QNB to that of OXO-M was determined1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
AID142224Binding affinity to muscarinic acetylcholine receptor was determined in presence of [3H]QNB radioligand (in vitro)1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Cholinergic activity of acetylenic imidazoles and related compounds.
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID142217Binding activity to muscarinic acetylcholine receptor in rat heart, assayed using [3H]-QNB as a radioligand.1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Chemical and biochemical studies of 2-propynylpyrrolidine derivatives. Restricted-rotation analogues of N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM-5).
AID141886Inhibition of [3H]- oxotremorine-M binding to human Muscarinic acetylcholine receptor M4 in CHO cell membranes2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID322941Binding affinity to human cloned muscarinic M2 receptor expressed in CHO cells2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Docking analyses on human muscarinic receptors: unveiling the subtypes peculiarities in agonists binding.
AID114478Central muscarinic activity administered intraperitoneally to mice, expressed as analgesia1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
5-Methyl-2-pyrrolidone analogues of oxotremorine as selective muscarinic agonists.
AID141858Binding affinity to Muscarinic acetylcholine receptor M1 by measuring its ability to displace [3H]pirenzepine from rat cerebral cortex1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Synthesis and pharmacological characterization of O-alkynyloximes of tropinone and N-methylpiperidinone as muscarinic agonists.
AID228329Ratio of Ki value for QNB to that of Ki value for Oxo-M.1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Cholinergic activity of acetylenic imidazoles and related compounds.
AID1510623Agonist activity at human Muscarinic acetylcholine receptor M4 expressed in HEK cells co-expressing Glosensor construct assessed as decrease in isoproterenol-induced cAMP accumulation at 10 uM to 0.3 nM incubated for 2 hrs in presence of isoproterenol and2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Discovery of Selective M4 Muscarinic Acetylcholine Receptor Agonists with Novel Carbamate Isosteres.
AID141552In vitro Binding affinity was measured against Muscarinic acetylcholine receptor on rat brain membranes using [3H]oxotremorine-M1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID141973Compound was evaluated for its ability to displace [3H]N-methylscopolamine ([3H]NMS) binding to cloned CHO cell lines expressing Muscarinic acetylcholine receptor M11998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.
AID142532Inhibition of [3H]- quinuclidinyl benzilate binding to human Muscarinic acetylcholine receptor M2 expressed in CHO cell membrane2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors.
AID101702Binding affinity at [3H]QNB and GppNHp radiolabeled muscarinic M2 receptor in rat heart.1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
The synthesis and biochemical pharmacology of enantiomerically pure methylated oxotremorine derivatives.
AID232955Inhibitory selectivity for Muscarinic receptors M2 and M11998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Synthesis and pharmacological characterization of O-alkynyloximes of tropinone and N-methylpiperidinone as muscarinic agonists.
AID141075Dissociation constant for complex with muscarinic acetylcholine receptor M3 of guinea pig ileum1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide.
AID232627Ratio of inhibitory activity against [3H]quinuclidinyl benzilate (QNB) binding in the absence of Zn to in the presence of Zn1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID230164The equipotent molar ratio relative to oxotremorine (EPMR)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Tertiary 3- and 4-haloalkylamine analogues of oxotremorine as prodrugs of potent muscarinic agonists.
AID231029Muscarinic 1 receptor agonistic activity as the selectivity ratio of Ki against [3H]-QNB+ Gpp(NH)p to that of [3H]PZ1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Chemical and biochemical studies of 2-propynylpyrrolidine derivatives. Restricted-rotation analogues of N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM-5).
AID142232Displacement of [3H]3-quinuclidinyl benzilate ([3H]-QNB) from muscarinic acetylcholine receptor of rat cerebral cortex1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide.
AID1510624Positive allosteric modulatory activity at human Muscarinic acetylcholine receptor M4 expressed in HEK cells co-expressing Glosensor construct assessed as as increase in acteylcholine-induced cAMP accumulation at 10 uM to 0.3 nM incubated for 7 mins in pr2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Discovery of Selective M4 Muscarinic Acetylcholine Receptor Agonists with Novel Carbamate Isosteres.
AID141132Tested for agonist activity at v in guinea pig ileum1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Stereoselectivity of muscarinic receptors in vivo and in vitro for oxotremorine analogues. N-[4-(tertiary amino)-2-butynyl]-5-methyl-2-pyrrolidones.
AID196039Inhibitory activity against norepinephrine (NE) uptake in rat whole brain synaptosome preparation; Not tested1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID197176Central postsynaptic muscarinic activity was measured by slow depolarization of the rat cervical ganglion in M1 model1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor.
AID142215Binding activity against Muscarinic acetylcholine receptor in rat cortex, using [3H]QNB as a radioligand.1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Chemical and biochemical studies of 2-propynylpyrrolidine derivatives. Restricted-rotation analogues of N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM-5).
AID141722Compound was evaluated for its binding affinity towards muscarinic acetylcholine receptor in rat cortex1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Synthesis and in vitro characterization of novel amino terminally modified oxotremorine derivatives for brain muscarinic receptors.
AID73897In vitro muscarinic activity against guinea pig ileum was determined1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Beta-lactam analogues of oxotremorine. 3- and 4-methyl-substituted 2-azetidinones.
AID141345In Vitro activity at the cloned Human Muscarinic acetylcholine receptor M3 determined by receptor selection and amplification technology (R-SAT)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors.
AID134768Toxicity was measured after iv administration1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Tertiary 3- and 4-haloalkylamine analogues of oxotremorine as prodrugs of potent muscarinic agonists.
AID112007Antagonistic activity against Scopolamine induced behavioral deficits in mice; Not tested1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID142216Binding activity to muscarinic acetylcholine receptor in rat heart, assayed using [3H]QNB as a radioligand in the presence of Gpp(NH)p.1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Chemical and biochemical studies of 2-propynylpyrrolidine derivatives. Restricted-rotation analogues of N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM-5).
AID232957Inhibitory selectivity for Muscarinic receptors M3 and M21998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Synthesis and pharmacological characterization of O-alkynyloximes of tropinone and N-methylpiperidinone as muscarinic agonists.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,869)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990970 (51.90)18.7374
1990's539 (28.84)18.2507
2000's237 (12.68)29.6817
2010's105 (5.62)24.3611
2020's18 (0.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.76 (24.57)
Research Supply Index7.57 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index57.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (0.31%)5.53%
Reviews15 (0.78%)6.00%
Case Studies3 (0.16%)4.05%
Observational0 (0.00%)0.25%
Other1,906 (98.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]